JPRN-jRCT2080222571
Unknown
Phase 3
A phase III long-term study to evaluate the safety and efficacy of TAC-202 in patients with perennial or seasonal allergic rhinitis.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Patients with perennial or seasonal allergic rhinitis.
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Enrollment
- 120
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who have been diagnosed with perennial allergic rhinitis and who have had related symptoms for 2 years or longer.
- •Subjects who have been diagnosed with seasonal allergic rhinitis and who have had related symptoms in Japanese ceder and Japanese cypress pollen season for 2 years or longer.
Exclusion Criteria
- •Subjects who previously developed anaphylaxis to antihistamine drugs, or ingredients of the investigational drug.
- •Subjects with any of the following complications that may hinder efficacy evaluation.
- •\- Vasomotor rhinitis
- •\- Eosinophilic rhinitis
- •\- Drug\-induced rhinitis
- •\- Viral conjunctivitis
- •\- Otitis media
- •\- Others (acute or chronic rhinitis, hypertrophic rhinitis, sinusitis, nasal polyps, repetitive nasal hemorrhage, treatment\-requiring nasal septal deviation, etc.)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
A phase III study of TAC-202 in patients with chronic idiopathic urticaria and pruritus accompanied by skin diseasesPatients with Chronic idiopathic urticaria, Eczema/Dermatitis, Prurigo, and Cutaneous pruritusJPRN-jRCT2080222478Taiho Pharmaceutical Co., Ltd.170
Active, not recruiting
Phase 1
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-GBAlkermes Inc500
Active, not recruiting
Phase 1
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-IEAlkermes Inc500
Active, not recruiting
Phase 1
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-ATAlkermes Inc500
Active, not recruiting
Phase 1
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-BGAlkermes Inc500